BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fuller CE, Schmidt RE, Roth KA, Burger PC, Scheithauer BW, Banerjee R, Trinkaus K, Lytle R, Perry A. Clinical Utility of Fluorescence In Situ Hybridization (FISH) in Morphologically Ambiguous Gliomas with Hybrid Oligodendroglial/Astrocytic Features. J Neuropathol Exp Neurol 2003;62:1118-28. [DOI: 10.1093/jnen/62.11.1118] [Cited by in Crossref: 87] [Cited by in F6Publishing: 90] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Ali RH, Alateeqi M, Jama H, Alrumaidhi N, Alqallaf A, Mohammed EM, Almurshed M, Bahzad S. Evaluation of the Oncomine Comprehensive Assay v3 panel for the detection of 1p/19q codeletion in oligodendroglial tumours. J Clin Pathol 2023;76:103-10. [PMID: 34489310 DOI: 10.1136/jclinpath-2021-207876] [Reference Citation Analysis]
2 Tirrò E, Massimino M, Broggi G, Romano C, Minasi S, Gianno F, Antonelli M, Motta G, Certo F, Altieri R, Manzella L, Caltabiano R, Barbagallo GMV, Buttarelli FR, Magro G, Giangaspero F, Vigneri P. A Custom DNA-Based NGS Panel for the Molecular Characterization of Patients With Diffuse Gliomas: Diagnostic and Therapeutic Applications. Front Oncol 2022;12:861078. [DOI: 10.3389/fonc.2022.861078] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Nuechterlein N, Shapiro LG, Holland EC, Cimino PJ. Machine learning modeling of genome-wide copy number alteration signatures reliably predicts IDH mutational status in adult diffuse glioma. Acta Neuropathol Commun 2021;9:191. [PMID: 34863298 DOI: 10.1186/s40478-021-01295-3] [Reference Citation Analysis]
4 Im S, Hyeon J, Rha E, Lee J, Choi HJ, Jung Y, Kim TJ. Classification of Diffuse Glioma Subtype from Clinical-Grade Pathological Images Using Deep Transfer Learning. Sensors (Basel) 2021;21:3500. [PMID: 34067934 DOI: 10.3390/s21103500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
5 Funakoshi Y, Hata N, Takigawa K, Arita H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Sako A, Umehara T, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iwaki T, Mizoguchi M. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma. Cancer Med 2021;10:3177-87. [PMID: 33838014 DOI: 10.1002/cam4.3860] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
6 Lin Z, Yang R, Li K, Yi G, Li Z, Guo J, Zhang Z, Junxiang P, Liu Y, Qi S, Huang G. Establishment of age group classification for risk stratification in glioma patients. BMC Neurol 2020;20:310. [PMID: 32819307 DOI: 10.1186/s12883-020-01888-w] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
7 Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Stupp R, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol 2019;21:1498-508. [PMID: 31276167 DOI: 10.1093/neuonc/noz119] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 9.3] [Reference Citation Analysis]
8 Riley RS, Almenara J, Fuller CE. Digital Micrographs in Pathology. Neuromethods 2020. [DOI: 10.1007/978-1-0716-0428-1_14] [Reference Citation Analysis]
9 Kim YZ, Kim CY, Lim J, Sung KS, Lee J, Oh HJ, Kang SG, Kang SH, Kong DS, Kim SH, Kim SH, Kim SH, Kim YJ, Kim EH, Kim IA, Kim HS, Roh TH, Park JS, Park HJ, Song SW, Yang SH, Yoon WS, Yoon HI, Lee ST, Lee SW, Lee YS, Wee CW, Chang JH, Jung TY, Jung HL, Cho JH, Choi SH, Choi HS, Hong JB, Lim DH, Chung DS; KSNO Guideline Working Group. The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01. Brain Tumor Res Treat 2019;7:63-73. [PMID: 31686436 DOI: 10.14791/btrt.2019.7.e42] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 Bruner JM, Louis DN, McLendon R, Rosenblum MK, Archambault WT, Most S, Tihan T. The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions. J Neuropathol Exp Neurol 2017;76:189-94. [PMID: 28395084 DOI: 10.1093/jnen/nlw122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Cimino PJ, Zager M, McFerrin L, Wirsching HG, Bolouri H, Hentschel B, von Deimling A, Jones D, Reifenberger G, Weller M, Holland EC. Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. Acta Neuropathol Commun 2017;5:39. [PMID: 28532485 DOI: 10.1186/s40478-017-0443-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 76] [Article Influence: 12.0] [Reference Citation Analysis]
12 Srebotnik-kirbiš I, Limbäck-stokin C. Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors. J Neurooncol 2016;129:415-22. [DOI: 10.1007/s11060-016-2211-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
13 Takeuchi H, Kitai R, Hosoda T, Yamada S, Hashimoto N, Kikuta K, Shimizu Y, Kimura H. Clinicopathologic features of small cell glioblastomas. J Neurooncol 2016;127:337-44. [PMID: 26725094 DOI: 10.1007/s11060-015-2038-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
14 Rodriguez F, Ho C. Special Techniques. Biomarkers in Neoplastic Neuropathology 2016. [DOI: 10.1007/978-3-319-20931-9_2] [Reference Citation Analysis]
15 Woehrer A, Hainfellner JA. Molecular diagnostics: techniques and recommendations for 1p/19q assessment. CNS Oncol 2015;4:295-306. [PMID: 26545171 DOI: 10.2217/cns.15.28] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
16 Duval C, de Tayrac M, Michaud K, Cabillic F, Paquet C, Gould PV, Saikali S. Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm. PLoS One 2015;10:e0132125. [PMID: 26135922 DOI: 10.1371/journal.pone.0132125] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
17 Reis GF, Pekmezci M, Hansen HM, Rice T, Marshall RE, Molinaro AM, Phillips JJ, Vogel H, Wiencke JK, Wrensch MR, Walsh KM, Perry A. CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. J Neuropathol Exp Neurol 2015;74:442-52. [PMID: 25853694 DOI: 10.1097/NEN.0000000000000188] [Cited by in Crossref: 99] [Cited by in F6Publishing: 102] [Article Influence: 12.4] [Reference Citation Analysis]
18 Le Rhun E, Taillibert S, Chamberlain MC. Anaplastic glioma: current treatment and management. Expert Rev Neurother 2015;15:601-20. [PMID: 25936680 DOI: 10.1586/14737175.2015.1042455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
19 Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 2015;129:679-93. [PMID: 25783747 DOI: 10.1007/s00401-015-1409-0] [Cited by in Crossref: 211] [Cited by in F6Publishing: 170] [Article Influence: 26.4] [Reference Citation Analysis]
20 Pekmezci M, Perry A. Practical molecular pathologic diagnosis of infiltrating gliomas. Surg Pathol Clin 2015;8:49-61. [PMID: 25783821 DOI: 10.1016/j.path.2014.10.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Gyure KA, Flanagan MB. The central nervous system. Silverberg's Principles and Practice of Surgical Pathology and Cytopathology 2015. [DOI: 10.1017/9781139137201.049] [Reference Citation Analysis]
22 Le Rhun E, Rhun EL, Taillibert S, Chamberlain MC. The future of high-grade glioma: Where we are and where are we going. Surg Neurol Int 2015;6:S9-S44. [PMID: 25722939 DOI: 10.4103/2152-7806.151331] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
23 Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015;129:133-46. [PMID: 25427834 DOI: 10.1007/s00401-014-1370-3] [Cited by in Crossref: 321] [Cited by in F6Publishing: 329] [Article Influence: 40.1] [Reference Citation Analysis]
24 Barresi V, Mondello S, Branca G, Rajan TS, Vitarelli E, Tuccari G. p-CREB expression in human gliomas: potential use in the differential diagnosis between astrocytoma and oligodendroglioma. Hum Pathol 2015;46:231-8. [PMID: 25476123 DOI: 10.1016/j.humpath.2014.10.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
25 Sahm F, Reuss D, Koelsche C, Capper D, Schittenhelm J, Heim S, Jones DT, Pfister SM, Herold-Mende C, Wick W, Mueller W, Hartmann C, Paulus W, von Deimling A. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol 2014;128:551-9. [PMID: 25143301 DOI: 10.1007/s00401-014-1326-7] [Cited by in Crossref: 208] [Cited by in F6Publishing: 166] [Article Influence: 23.1] [Reference Citation Analysis]
26 Jiang H, Zhang Z, Ren X, Zeng W, Jia W, Wang J, Lin S. 1p/19q-driven prognostic molecular classification for high-grade oligodendroglial tumors. J Neurooncol 2014;120:607-14. [DOI: 10.1007/s11060-014-1593-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
27 Clark KH, Villano JL, Nikiforova MN, Hamilton RL, Horbinski C. 1p/19q testing has no significance in the workup of glioblastomas. Neuropathol Appl Neurobiol 2013;39:706-17. [PMID: 23363074 DOI: 10.1111/nan.12031] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 4.0] [Reference Citation Analysis]
28 Senetta R, Verdun di Cantogno L, Chiusa L, Castellano I, Gugliotta P, Sapino A, Cassoni P. A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors. J Neuropathol Exp Neurol 2013;72:432-41. [PMID: 23584201 DOI: 10.1097/NEN.0b013e3182901f41] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
29 Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S. 1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. Neuro Oncol 2013;15:775-82. [PMID: 23486687 DOI: 10.1093/neuonc/not027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
30 Clark K, Voronovich Z, Horbinski C. How molecular testing can help (and hurt) in the workup of gliomas. Am J Clin Pathol 2013;139:275-88. [PMID: 23429363 DOI: 10.1309/AJCPFO8IIDNBIJ8Y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
31 Theeler BJ, Yung WK, Fuller GN, De Groot JF. Moving toward molecular classification of diffuse gliomas in adults. Neurology 2012;79:1917-26. [PMID: 23109653 DOI: 10.1212/WNL.0b013e318271f7cb] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 5.2] [Reference Citation Analysis]
32 Ohgaki H. Contribution of Molecular Biology to the Classification of Low-Grade Diffuse Glioma. Diffuse Low-Grade Gliomas in Adults 2013. [DOI: 10.1007/978-1-4471-2213-5_5] [Reference Citation Analysis]
33 de Groot JF. Prediction of response to chemotherapy in anaplastic glioma: how many markers does it take? J Clin Oncol 2013;31:297-8. [PMID: 23269985 DOI: 10.1200/JCO.2012.46.9627] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
34 Horbinski C. Something old and something new about molecular diagnostics in gliomas. Surg Pathol Clin 2012;5:919-39. [PMID: 23459421 DOI: 10.1016/j.path.2012.09.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
35 Choucair K, Ejdelman J, Brimo F, Aprikian A, Chevalier S, Lapointe J. PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity. BMC Cancer 2012;12:543. [PMID: 23171135 DOI: 10.1186/1471-2407-12-543] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.1] [Reference Citation Analysis]
36 Kanno H, Nishihara H, Narita T, Yamaguchi S, Kobayashi H, Tanino M, Kimura T, Terasaka S, Tanaka S. Prognostic implication of histological oligodendroglial tumor component: clinicopathological analysis of 111 cases of malignant gliomas. PLoS One 2012;7:e41669. [PMID: 22911839 DOI: 10.1371/journal.pone.0041669] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
37 Rudà R, Trevisan E, Soffietti R. Low-grade gliomas. Handb Clin Neurol 2012;105:437-50. [PMID: 22230511 DOI: 10.1016/B978-0-444-53502-3.00001-X] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
38 Horbinski C, Nikiforova MN, Hobbs J, Bortoluzzi S, Cieply K, Dacic S, Hamilton RL. The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas. J Neuropathol Exp Neurol 2012;71:73-82. [PMID: 22157622 DOI: 10.1097/NEN.0b013e318240fa65] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
39 Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, Shukla S, Somasundaram K, Mahapatra AK, Kale SS, Sarkar C. Molecular profile of oligodendrogliomas in young patients. Neuro Oncol 2011;13:1099-106. [PMID: 21937591 DOI: 10.1093/neuonc/nor146] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.3] [Reference Citation Analysis]
40 Tanaka Y, Nobusawa S, Yagi S, Ikota H, Yokoo H, Nakazato Y. Anaplastic oligodendroglioma with ganglioglioma-like maturation. Brain Tumor Pathol 2012;29:221-8. [PMID: 22231405 DOI: 10.1007/s10014-011-0078-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
41 Lindberg N, Uhrbom L. Oligodendroglioma Models. Neuromethods 2012. [DOI: 10.1007/7657_2012_35] [Reference Citation Analysis]
42 Scheie D, Meling TR, Cvancarova M, Skullerud K, Mørk S, Lote K, Eide TJ, Helseth E, Beiske K. Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases. Neuro Oncol 2011;13:1225-33. [PMID: 21856683 DOI: 10.1093/neuonc/nor114] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
43 Kohsaka S, Sasai K, Takahashi K, Akagi T, Tanino M, Kimura T, Nishihara H, Tanaka S. A population of BJ fibroblasts escaped from Ras-induced senescence susceptible to transformation. Biochem Biophys Res Commun 2011;410:878-84. [PMID: 21703241 DOI: 10.1016/j.bbrc.2011.06.082] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
44 Hattab EM, Martin SE, Shapiro SA, Cheng L. Pleomorphic xanthoastrocytoma and oligodendroglioma: collision of 2 morphologically and genetically distinct anaplastic components: Case report. JNS 2011;114:1648-53. [DOI: 10.3171/2010.11.jns10739] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
45 Klink B, Schlingelhof B, Klink M, Stout-Weider K, Patt S, Schrock E. Glioblastomas with oligodendroglial component-common origin of the different histological parts and genetic subclassification. Cell Oncol (Dordr) 2011;34:261-75. [PMID: 21538026 DOI: 10.1007/s13402-011-0034-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
46 Kros JM. Grading of gliomas: the road from eminence to evidence. J Neuropathol Exp Neurol 2011;70:101-9. [PMID: 21343878 DOI: 10.1097/NEN.0b013e31820681aa] [Cited by in Crossref: 43] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
47 Horbinski C, Miller CR, Perry A. Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. Brain Pathol 2011;21:57-73. [PMID: 21129060 DOI: 10.1111/j.1750-3639.2010.00453.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 81] [Article Influence: 6.6] [Reference Citation Analysis]
48 Srividya MR, Thota B, Shailaja BC, Arivazhagan A, Thennarasu K, Chandramouli BA, Hegde AS, Santosh V. Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: a prospective translational study on a uniformly treated cohort of adult patients. Neuropathology 2011;31:376-83. [PMID: 21134002 DOI: 10.1111/j.1440-1789.2010.01178.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
49 Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y. Molecular classification of low-grade diffuse gliomas. Am J Pathol. 2010;177:2708-2714. [PMID: 21075857 DOI: 10.2353/ajpath.2010.100680] [Cited by in Crossref: 194] [Cited by in F6Publishing: 198] [Article Influence: 14.9] [Reference Citation Analysis]
50 Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan T, Chatelut E, Le Deley MC, Paoletti X, Saint-Rose C, Leblond P, Morland B, Gentet JC, Méresse V, Vassal G; ITCC (Innovative Therapies for Children with Cancer) European Consortium. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol 2011;13:109-18. [PMID: 20974795 DOI: 10.1093/neuonc/noq141] [Cited by in Crossref: 113] [Cited by in F6Publishing: 117] [Article Influence: 8.7] [Reference Citation Analysis]
51 Horbinski C. Practical molecular diagnostics in neuropathology: making a tough job a little easier. Semin Diagn Pathol 2010;27:105-13. [PMID: 20860314 DOI: 10.1053/j.semdp.2010.04.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
52 Kita D, Hayashi Y, Watanabe T, Korshunov A, von Deimling A, Nakada M, Kasahara Y, Zen Y, Hamada J, Hayashi Y. Secondary anaplastic astrocytoma developing in a young adult with autoimmune lymphoproliferative syndrome (ALPS). Neuropathol Appl Neurobiol 2011;37:423-7. [PMID: 20846185 DOI: 10.1111/j.1365-2990.2010.01123.x] [Reference Citation Analysis]
53 Idbaih A, Dalmasso C, Kouwenhoven M, Jeuken J, Carpentier C, Gorlia T, Kros JM, French P, Teepen J, Broët P, Delattre O, Mokhtari K, Sanson M, Delattre JY, van den Bent M, Hoang-Xuan K. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J Neurooncol 2011;103:221-30. [PMID: 20820870 DOI: 10.1007/s11060-010-0380-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
54 Yang LS, Huang FP, Zheng K, Zhang HS, Zhou X, Bao XH, Zheng JJ, Chang C, Zhou LF. Factors affecting prognosis of patients with intracranial anaplastic oligodendrogliomas: a single institutional review of 70 patients. J Neurooncol 2010;100:113-20. [PMID: 20195700 DOI: 10.1007/s11060-010-0146-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
55 Mckeever PE. Immunohistology of the Nervous System. Diagnostic Immunohistochemistry 2010. [DOI: 10.1016/b978-1-4160-5766-6.00024-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
56 Brat DJ, Perry A. Astrocytic and Oligodendroglial Tumors. Practical Surgical Neuropathology. Elsevier; 2010. pp. 63-102. [DOI: 10.1016/b978-0-443-06982-6.00005-5] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
57 Riemenschneider MJ, Reifenberger G. Molecular neuropathology of low-grade gliomas and its clinical impact. Advances and Technical Standards in Neurosurgery 2010. [DOI: 10.1007/978-3-211-99481-8_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
58 Capelle L, Oei P, Teoh H, Hamilton D, Palmer D, Low I, Campbell G. Retrospective review of prognostic factors, including 1p19q deletion, in low-grade oligodendrogliomas and a review of recent published works. J Med Imaging Radiat Oncol 2009;53:305-9. [PMID: 19624298 DOI: 10.1111/j.1754-9485.2009.02074.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
59 Gadji M, Fortin D, Tsanaclis AM, Drouin R. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas? Cancer Genet Cytogenet 2009;194:12-22. [PMID: 19737649 DOI: 10.1016/j.cancergencyto.2009.05.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
60 Vital AL, Tabernero MD, Crespo I, Rebelo O, Tão H, Gomes F, Lopes MC, Orfao A. Intratumoral patterns of clonal evolution in gliomas. Neurogenetics 2010;11:227-39. [DOI: 10.1007/s10048-009-0217-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
61 Fischer I, de la Cruz C, Rivera AL, Aldape K. Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH). Diagn Mol Pathol 2008;17:227-30. [PMID: 18382350 DOI: 10.1097/PDM.0b013e3181642230] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
62 Scheie D, Cvancarova M, Mørk S, Skullerud K, Andresen PA, Benestad I, Helseth E, Meling T, Beiske K. Can morphology predict 1p/19q loss in oligodendroglial tumours?: Can morphology predict 1p/19q loss. Histopathology 2008;53:578-87. [DOI: 10.1111/j.1365-2559.2008.03160.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
63 Trembath D, Miller CR, Perry A. Gray zones in brain tumor classification: evolving concepts. Adv Anat Pathol 2008;15:287-97. [PMID: 18724102 DOI: 10.1097/PAP.0b013e3181836a03] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.7] [Reference Citation Analysis]
64 Pinto LW, Araújo MB, Vettore AL, Wernersbach L, Leite AC, Chimelli LM, Soares FA. Glioblastomas: correlation between oligodendroglial components, genetic abnormalities, and prognosis. Virchows Arch 2008;452:481-90. [PMID: 18351387 DOI: 10.1007/s00428-007-0562-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
65 Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice]. Rev Neurol (Paris) 2008;164:595-604. [PMID: 18565359 DOI: 10.1016/j.neurol.2008.04.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
66 Louis D, Reifenberger G, Brat D. Tumours. Greenfield's Neuropathology Eighth Edition. 2 Volume Set and DVD 2008. [DOI: 10.1201/b13319-24] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
67 Miller CR, Dunham CP, Scheithauer BW, Perry A. Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 2006;24:5419-26. [PMID: 17135643 DOI: 10.1200/JCO.2006.08.1497] [Cited by in Crossref: 135] [Cited by in F6Publishing: 149] [Article Influence: 7.9] [Reference Citation Analysis]
68 Siker ML, Chakravarti A, Mehta MP. Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Critical Reviews in Oncology/Hematology 2006;60:99-111. [DOI: 10.1016/j.critrevonc.2006.04.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
69 Scheie D, Andresen PA, Cvancarova M, Bø AS, Helseth E, Skullerud K, Beiske K. Fluorescence In Situ Hybridization (FISH) on Touch Preparations: A Reliable Method for Detecting Loss of Heterozygosity at 1p and 19q in Oligodendroglial Tumors. American Journal of Surgical Pathology 2006;30:828-37. [DOI: 10.1097/01.pas.0000213250.44822.2e] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.2] [Reference Citation Analysis]
70 Eoli M, Bissola L, Bruzzone MG, Pollo B, Maccagnano C, De Simone T, Valletta L, Silvani A, Bianchessi D, Broggi G, Boiardi A, Finocchiaro G. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 2006;119:84-90. [PMID: 16432842 DOI: 10.1002/ijc.21759] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 2.3] [Reference Citation Analysis]
71 Bannykh SI, Stolt CC, Kim J, Perry A, Wegner M. Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J Neurooncol 2006;76:115-27. [PMID: 16205963 DOI: 10.1007/s11060-005-5533-x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
72 Belaud-Rotureau MA, Meunier N, Eimer S, Vital A, Loiseau H, Merlio JP. Automatized assessment of 1p36-19q13 status in gliomas by interphase FISH assay on touch imprints of frozen tumours. Acta Neuropathol 2006;111:255-63. [PMID: 16453145 DOI: 10.1007/s00401-005-0001-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
73 Wemmert S, Ketter R, Rahnenführer J, Beerenwinkel N, Strowitzki M, Feiden W, Hartmann C, Lengauer T, Stockhammer F, Zang KD, Meese E, Steudel WI, von Deimling A, Urbschat S. Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment. Neoplasia 2005;7:883-93. [PMID: 16242071 DOI: 10.1593/neo.05307] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 2.3] [Reference Citation Analysis]
74 Fuller C, Helton K, Dalton J, Fouladi M, Kun L, Burger P. Polar spongioblastoma of the spinal cord: a case report. Pediatr Dev Pathol 2006;9:75-80. [PMID: 16808641 DOI: 10.2350/08-05-0099.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
75 Scheck AC. Chemotherapy Resistance. Handbook of Brain Tumor Chemotherapy 2006. [DOI: 10.1016/b978-012088410-0/50044-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
76 Mcgregor LM, Rao BN, Davidoff AM, Billups CA, Hongeng S, Santana VM, Hill DA, Fuller C, Furman WL. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: The St. Jude Children's Research Hospital experience. Cancer 2005;104:2837-46. [DOI: 10.1002/cncr.21566] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.9] [Reference Citation Analysis]
77 Cavaliere R, Lopes MBS, Schiff D. Low-grade gliomas: an update on pathology and therapy. The Lancet Neurology 2005;4:760-70. [DOI: 10.1016/s1474-4422(05)70222-2] [Cited by in Crossref: 89] [Cited by in F6Publishing: 94] [Article Influence: 4.9] [Reference Citation Analysis]
78 Korshunov A, Sycheva R, Golanov A. The prognostic relevance of molecular alterations in glioblastomas for patients age < 50 years. Cancer 2005;104:825-32. [PMID: 15981281 DOI: 10.1002/cncr.21221] [Cited by in Crossref: 50] [Cited by in F6Publishing: 57] [Article Influence: 2.8] [Reference Citation Analysis]
79 Laigle-donadey F, Benouaich-amiel A, Hoang-xuan K, Sanson M. Biologie moléculaire des tumeurs oligodendrogliales. Neurochirurgie 2005;51:260-8. [DOI: 10.1016/s0028-3770(05)83487-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
80 Korshunov A, Sycheva R, Gorelyshev S, Golanov A. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol 2005;18:1258-63. [PMID: 15832192 DOI: 10.1038/modpathol.3800415] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
81 Kitayama Y. Modified fluorescence in situ hybridization methods using pathology archives. Neuropathology 2005;25:269-73. [DOI: 10.1111/j.1440-1789.2005.00628.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
82 Walker C, du Plessis DG, Joyce KA, Fildes D, Gee A, Haylock B, Husband D, Smith T, Broome J, Warnke PC. Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol 2005;57:855-65. [PMID: 15929038 DOI: 10.1002/ana.20496] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 2.9] [Reference Citation Analysis]
83 Fuller CE, Perry A. Molecular diagnostics in central nervous system tumors. Adv Anat Pathol 2005;12:180-94. [PMID: 16096380 DOI: 10.1097/01.pap.0000175117.47918.f7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 2.2] [Reference Citation Analysis]
84 Tanaka Y, Yokoo H, Komori T, Makita Y, Ishizawa T, Hirose T, Ebato M, Shibahara J, Tsukayama C, Shibuya M, Nakazato Y. A distinct pattern of Olig2-positive cellular distribution in papillary glioneuronal tumors: a manifestation of the oligodendroglial phenotype? Acta Neuropathol 2005;110:39-47. [PMID: 15906048 DOI: 10.1007/s00401-005-1018-4] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 2.4] [Reference Citation Analysis]
85 Perry A, Aldape KD, George DH, Burger PC. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 2004;101:2318-26. [PMID: 15470710 DOI: 10.1002/cncr.20625] [Cited by in Crossref: 101] [Cited by in F6Publishing: 114] [Article Influence: 5.3] [Reference Citation Analysis]
86 Palfi S, Swanson KR, De Boüard S, Chrétien F, Oliveira R, Gherardi RK, Kros JM, Peschanski M, Christov C. Correlation of in vitro infiltration with glioma histological type in organotypic brain slices. Br J Cancer 2004;91:745-52. [PMID: 15292940 DOI: 10.1038/sj.bjc.6602048] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 1.5] [Reference Citation Analysis]
87 Armanios MY, Grossman SA, Yang SC, White B, Perry A, Burger PC, Orens JB. Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature. Neuro Oncol 2004;6:259-63. [PMID: 15279719 DOI: 10.1215/S1152851703000474] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 3.1] [Reference Citation Analysis]